Jerome Kuhnlein, MD
Interventional Cardiology · Saint Joseph, MINPI 1619937315
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,400 of the $11,403 with a category attached, or 64.9%. E.r. Squibb & Sons, L.L.C. accounts for 73.2% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $4,527 and has fallen 84.2% since, to $715 in 2025.
Across 208 payments — averaging $54.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$8K
- Novartis$547
- Boston Scientific$398
- Johnson & Johnson$349
- Pfizer$246
- Amgen$224
- plus $1K from 21 others
Across 28 payments — averaging $853.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$24K
What the payments were for
- Consulting fees$3003%
- Speaking & faculty fees$7,40065%
- Food & beverage$3,67232%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 41 | $8,345 |
| Novartis | 35 | $547 |
| Boston Scientific | 14 | $398 |
| Johnson & Johnson | 28 | $349 |
| Pfizer | 12 | $246 |
| Amgen | 7 | $224 |
| Boehringer Ingelheim | 9 | $199 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $194 |
| AstraZeneca(2 entities) | 10 | $143 |
| Abiomed | 4 | $92 |
| Alnylam Pharmaceuticals Inc. | 4 | $91 |
| Inspire Medical Systems, Inc. | 2 | $71 |
| Amarin Pharma, Inc. | 4 | $66 |
| Scpharmaceuticals Inc. | 3 | $58 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Gilead | 3 | $48 |
| Actelion Pharmaceuticals US, Inc. | 3 | $45 |
| Bridgebio Pharma, Inc. | 2 | $43 |
| Bayer | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Merck | 1 | $31 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| GSK | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
| Elutia, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$7,400
How this compares
$11,403 in reported general payments places this provider in the 65th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 826 | $925,847 |
| EntrestoSacubitril/Valsartan | 104 | $134,588 |
| XareltoRivaroxaban | 80 | $107,969 |
| MultaqDronedarone Hcl | 40 | $65,234 |
| Repatha SureclickEvolocumab | 31 | $36,627 |
| FarxigaDapagliflozin Propanediol | 15 | $22,673 |
| JardianceEmpagliflozin | 12 | $12,980 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 32 | $11,522 |
| Ranolazine ErRanolazine | 74 | $7,631 |
| Metoprolol Succinate | 439 | $7,244 |
| Metoprolol Tartrate | 682 | $5,217 |
| Losartan Potassium | 392 | $4,586 |
| Atorvastatin Calcium | 444 | $4,514 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 94 | $3,802 |
| Propafenone Hcl ErPropafenone Hcl | 25 | $3,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $246 | $925,847826 claims |
| NovartisEntresto | $547 | $134,588104 claims |
| Johnson & JohnsonXarelto | $349 | $107,96980 claims |
| Sanofi-aventis U.S. LLCMultaq | $16 | $65,23440 claims |
| AstraZenecaFarxiga | $143 | $22,67315 claims |
| Boehringer IngelheimJardiance | $199 | $12,98012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Saint Joseph
- Dilip AroraSaint Joseph$18K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
- Vishal GuptaKalamazoo$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.